- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NEUROSENSE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Di | NeuroSense Therapeutics Ltd. - F-1, Registration statement for certain foreign private issuers | - | SEC Filings | ||
| 31.10. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 28.10. | NeuroSense plant FDA-Treffen für ALS-Medikamentenstudie | 5 | Investing.com Deutsch | ||
| 28.10. | NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission | 63 | PR Newswire | Meeting discussion to focus on finalizing Phase 3 study design and NDA readiness, ensuring a clear regulatory path for submission based on trial success
Parallel... ► Artikel lesen | |
| 28.10. | EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission | 8 | Benzinga.com | ||
| 24.10. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 24.10. | NeuroSense: New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients | 63 | PR Newswire | Groundbreaking PARADIGM Trial Offers New Hope for ALS Treatment
CAMBRIDGE, Mass., Oct. 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage... ► Artikel lesen | |
| 15.10. | NeuroSense strebt frühzeitige Zulassung für ALS-Medikament in Kanada an | 3 | Investing.com Deutsch | ||
| 09.10. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 24.09. | NeuroSense Reports Patent Grant For PrimeC Formulation | 1 | RTTNews | ||
| 24.09. | NeuroSense extends PrimeC patent protection to 2042 | 3 | Investing.com | ||
| 24.09. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 24.09. | NeuroSense regains compliance with minimum bid price rule | 1 | Seeking Alpha | ||
| 16.09. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 09.09. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 30.08. | NeuroSense Therapeutics receives Nasdaq minimum bid price notification | 4 | Seeking Alpha | ||
| 30.08. | NeuroSense faces Nasdaq delisting over share price | 3 | Investing.com | ||
| 30.08. | NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification | 268 | PR Newswire | CAMBRIDGE, Mass., Aug. 30, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments... ► Artikel lesen | |
| 28.08. | EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug | 6 | Benzinga.com | ||
| 26.08. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings |
Seite:
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 0,900 | -21,74 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,364 | -1,62 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,450 | -2,16 % | Cardiol Therapeutics präsentiert klinische Ergebnisse der Phase-II-Pilotstudie MAvERIC zu rezidivierender Perikarditis bei den Scientific Sessions 2024 der American Heart Association | - Eine
deutliche und rasche Reduktion sowohl der Perikarditis-bedingten Schmerzen als auch der Entzündungen wurde während der 26-wöchigen Studie aufrechterhalten
- Anzahl... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,100 | +0,83 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
| RECURSION PHARMACEUTICALS | 6,040 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,480 | 0,00 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
| ONCOLYTICS BIOTECH | 0,950 | +0,53 % | Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2024 Earnings Call Transcript | ||
| CIDARA THERAPEUTICS | 14,700 | +2,08 % | Cidara Therapeutics, Inc.: Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results | SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 16,190 | 0,00 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,950 | 0,00 % | Assertio Holdings-Direktorin Heather Mason kauft Aktien im Wert von 60.000 US-Dollar | ||
| SIGA TECHNOLOGIES | 6,250 | 0,00 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,370 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| VIR BIOTECHNOLOGY | 6,740 | 0,00 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,550 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 16,500 | -2,94 % | Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level |
NEUROSENSE THERAPEUTICS LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEUROSENSE THERAPEUTICS LTD finden Sie auf Wallstreet Online.
